Koers Cyxone AB (publ) Nasdaq Stockholm
Aandelen
SE0007815428
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 24,62 mln. 2,33 mln. 2,18 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -28 mln. -2,65 mln. -2,48 mln. | Nettowinst (verlies) 2025 * | -38 mln. -3,6 mln. -3,37 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 1 mln. 94,76K 88,68K | Nettoliquiditeiten 2025 * | 41 mln. 3,89 mln. 3,64 mln. | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,88
x | K/w-verhouding 2025 * |
-0,63
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 70,53% |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Oredsson
CHM | Chairman | 64 | 01-01-23 |
Jürgen Reess
BRD | Director/Board Member | 62 | 01-01-23 |
Andrew Scorey
BRD | Director/Board Member | 57 | 01-01-23 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,03% | 9,11 mld. | |
-24,00% | 4,44 mld. | |
+13,37% | 4,24 mld. | |
+31,17% | 4,03 mld. | |
+7,43% | 2,14 mld. | |
-34,04% | 1,9 mld. | |
+7,56% | 1,94 mld. | |
-0,50% | 1,64 mld. | |
-47,93% | 1,63 mld. |